Rainbownewsline

DelveInsight Business Research LLP

DelveInsight’s ‘Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Generalized Anxiety Disorder in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Highlights for Generalized Anxiety Disorder 

• Key Companies working in the Generalized Anxiety Disorder Market are MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics, and many others 

• Key Therapies included in the Generalized Anxiety Disorder market are as follows Paroxetine, Sertraline, CD-008-0045, Afobazol, and many others 

• The Generalized Anxiety Disorder market size in the seven major markets was approximately USD 1,500 million in 2021.

• The CAGR for the Generalized Anxiety Disorder market is XX%.

Generalized Anxiety Disorder Overview

Generalized anxiety disorder involves persistent and excessive worry that interferes with daily activities. This ongoing worry and tension may be accompanied by physical symptoms, such as restlessness, feeling on edge or easily fatigued, difficulty concentrating, muscle tension, or problems sleeping. Often the worries focus on everyday things such as job responsibilities, family health, or minor matters such as chores, car repairs, or appointments.

Generalized Anxiety Disorder can go undiagnosed because of a focus on physical symptoms and the stigma of mental illness. However, people with Generalized Anxiety Disorder can have meaningful lives and can function socially as well, when the anxiety level is mild-to-moderate or when they are taking some kind of treatment. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) lists separation anxiety, selective mutism, specific phobia, social anxiety disorder (also called social phobia), panic disorder, agoraphobia, generalized anxiety, substance abuse/medication-induced anxiety, an anxiety disorder caused by another medical condition.

Generalized Anxiety Disorder Epidemiology Insights 

• The Prevalence of the clinically significant component of the Generalized Anxiety Disorder syndrome could be as high as 5% to 8% of the general population compared with the 1.5% to 3.0% found in epidemiologic studies of Generalized Anxiety Disorder 

Click here to learn more about the Generalized Anxiety Disorder Market Landscape

The Report Covers the Generalized Anxiety Disorder Epidemiology Segmented by:

• Generalized Anxiety Disorder prevalent cases 

• Generalized Anxiety Disorder incident cases 

• Generalized Anxiety Disorder treatment cases 

• Generalized Anxiety Disorder diagnosed cases 

Generalized Anxiety Disorder Market Outlook

The Generalized Anxiety Disorder market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Generalized Anxiety Disorder market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology. This segment gives a thorough detail of the Generalized Anxiety Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Generalized Anxiety Disorder market in the 7MM is expected to change in the study period 2019–2032.

The United States: Generalized Anxiety Disorder Market Outlook

This section provides the total Generalized Anxiety Disorder market size and market size of Generalized Anxiety Disorder by therapies in the United States.

Among the pharmacological therapies, SSRIs (Paroxetine, Escitalopram, Sertraline, Fluoxetine, and others) are commonly used as the first line of therapy. They can relieve anxiety symptoms and help reduce the symptoms of depression that often accompany anxiety disorders. Side effects of SSRIs include nausea, insomnia, and sexual dysfunction. If treatment with SSRIs does not work, other classes of medications, such as SNRIs, which include duloxetine and venlafaxine, and others are recommended. They have a similar effect to SSRIs.

EU-5 Countries: Generalized Anxiety Disorder Market Outlook

The total Generalized Anxiety Disorder market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

Japan: Generalized Anxiety Disorder Market Outlook

The total Generalized Anxiety Disorder market size and market size by therapies of Generalized Anxiety Disorder in Japan are also mentioned.

 Key Companies Working in the Generalized Anxiety Disorder Market

MindMedVistaGen TherapeuticsActavisTakeda PharmaceuticalsBionomics

And many others 

 Generalized Anxiety Disorder Therapies Covered and Analyzed in the Report

• MM-120

• Paroxetine, 

• Sertraline, 

• CD-008-0045, 

• Afobazol

And many others

Learn about the Key Companies and Emerging Therapies in Generalized Anxiety Disorder 

Table of Contents 

1. Key Insights 

2. Generalized Anxiety Disorder Introduction 

3. Executive Summary of Generalized Anxiety Disorder       –     

4. Disease Background and Overview

5. Epidemiology and patient population

6. Generalized Anxiety Disorder Emerging Therapies

7. Generalized Anxiety Disorder Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Generalized Anxiety Disorder Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services